Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643558 | 0.81 | MEN1 (0.53) | MEN1KMT2AKDM4EHKDC1CMA1 | |
| SCHEMBL2643315 | 0.79 | F2 (0.44) | MEN1KMT2AKDM4EHKDC1ALDH1A1 | |
| SCHEMBL2660345 | 0.79 | F2 (0.44) | MEN1KMT2AKDM4EHKDC1ALDH1A1 | |
| SCHEMBL2644855 | 0.75 | KDM4E (0.57) | MEN1KMT2AKDM4EHKDC1CMA1 | |
| SCHEMBL2644833 | 0.75 | KDM4E (0.46) | MEN1KMT2AKDM4EHKDC1CMA1 | |
| SCHEMBL2644568 | 0.73 | MEN1 (0.45) | MEN1KMT2AKDM4EHKDC1CMA1 | |
| SCHEMBL2643272 | 0.72 | KDM4E (0.46) | MEN1KMT2AKDM4EHKDC1CMA1 | |
| SCHEMBL2644259 | 0.70 | MEN1 (0.46) | MEN1KMT2AKDM4EHKDC1ALDH1A1 | |
| SCHEMBL2643789 | 0.70 | KMT2A (0.49) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL2643195 | 0.68 | MEN1 (0.53) | MEN1KMT2AALDH1A1PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | GCK, GCKR, PDXK | MEN1 4513/4885KMT2A 3063/4885LDHA 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.